PlainPharmaWatch

CMS Open Payments · Program Year 2024

Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc. reported $1,048,823.39 across General Payments, Research, and Ownership to 2,161 physicians and teaching hospitals across 2,178 transactions.

See the rankings → How this is sourced
$1.0M Above-median payer
All-tracks total
2,178 Top quartile volume
Transactions
2,161 Top quartile reach
Recipients
+$23.0K
General Payments vs PY2023

Amphastar Pharmaceuticals, Inc. reported $1,048,823.39 across all CMS Open Payments tracks (General + Research + Ownership) to 2,161 physicians and teaching hospitals in Program Year 2024 - ranking #613 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $41,335.88, averaging $485.34 per recipient.

How Amphastar Pharmaceuticals, Inc.'s $1.0M all-tracks total breaks down

Amphastar Pharmaceuticals, Inc.'s payment reach score

Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.

Overall reach score

F

21/100

Total payments

F

20/100

Transaction volume

F

26/100

Physician reach

F

26/100

Payment type diversity

F

10/100

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer amphastar-pharmaceuticals-inc Amphastar Pharmaceuticals, Inc.

$1.0M · #613/1,925 · 0.0% industry · PY2024

  • TOT $1.0M
  • RANK #613
  • SHARE 0.0%
  • TXN 2,178
  • RCP 2,161
  • CAT 1
  • GEN $41.3K
  • ΔGEN +$23.0K
  • TOP1 0.7%
  • PY 2024

Volume peers

Nearest volume peer: BioPoly LLC ($1.1M)

Synergy Products LLC$1.1MBioPoly LLC$1.1MAmphastar Pharmaceuticals, I…$1.0MRadius Health, Inc.$1.0MiotaMotion, Inc.$1.0M
All-tracks payment totals near Amphastar Pharmaceuticals, Inc. (CMS Open Payments PY2024)

Amphastar Pharmaceuticals, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Amphastar Pharmaceuticals, Inc.'s CMS-reported General Payments increased by $23.0K (+125.7%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: AMPHASTAR PHARMACEUTICALS, INC.PY2023: AMPHASTAR PHARMACEUTICALS, INC.PY2024: Amphastar Pharmaceuticals, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$18.3KPY2024$41.3K
PY2023
$18,317.68
PY2024
$41,335.88

What the Data Shows for Amphastar Pharmaceuticals, Inc.

The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Amphastar Pharmaceuticals, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.

Of the 1 general-payment categories charted below, "Food and Beverage" is the largest at $41.3K across 2,161 transactions, 100.0% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Across 1 types of general payments, Amphastar Pharmaceuticals, Inc.'s largest category was "Food and Beverage" at $41.3K - 100.0% of General Payments.

How Amphastar Pharmaceuticals, Inc. divides its payments

How the reported total splits across payment categories

1. Food and Beverage$41.3K
Payment Type Amount Transactions
Food and Beverage $41.3K 2,161

Recipient Concentration in General Payments

The five largest recipient relationships account for $1,188.75 (2.9%) of $41,335.88 in this company's General Payments records across 1,339 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Amphastar Pharmaceuticals, Inc.

The five named recipients with the highest reported General Payments from this company

Eva Toth$278.69Mark Stesin$269.82Pablito G Nagpala$230.58Melissa R Vansickel$224.36Nina Le$185.30
  1. 1

    Eva Toth

    $278.69 across 49 reported transactions

  2. 2

    Mark Stesin

    $269.82 across 6 reported transactions

  3. 3

    Pablito G Nagpala

    $230.58 across 20 reported transactions

  4. 4

    Melissa R Vansickel

    $224.36 across 4 reported transactions

  5. 5

    Nina Le

    $185.30 across 4 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Spend vs. Concentration

Amphastar Pharmaceuticals, Inc. ranks #613 of 1,925 by total payments (top 32% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,826 of 1,838 by HHI (bottom 1% least concentrated), a wider distribution than most similarly sized payers.

012.324.737.049.47.510.31315.818.5Total payments ($M)Concentration (HHI, 0-10,000)
Amphastar Pharmaceuticals, Inc. (highlighted) among its 12 nearest HHI-concentration neighbors, Program Year 2024. Dashed lines mark this neighborhood's median payment total and median HHI. Hover a point for the company name. Source: company_concentration (CMS Open Payments general-payment recipients).
View all 12 companies in this HHI neighborhood as a list

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Amphastar Pharmaceuticals, Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Amphastar Pharmaceuticals, Inc..

Janssen Biotech, Inc.

HHI 13

180 Medical, Inc.

HHI 13

E.R. Squibb & Sons, L.L.C.

HHI 12

Aspira Women's Health Inc

HHI 12

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Amphastar Pharmaceuticals, Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Put this to use

Amphastar Pharmaceuticals, Inc. ranks #613 of 1,925 by all-tracks total payments, led by "Food and Beverage".

Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Amphastar Pharmaceuticals, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.